Parameter
| Biomarker | ZEB1 | Full name | Zinc finger E-box-binding homeobox 1 | Molecular Type | Protein / Nucleic acid（RNA） |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis |
| Disease | Breast Cancer | Disease Subtypes | / | ||
| Organ | Breast | Test Sample / Technology Platform | Tumor tissues (IHC, qPCR, NGS) | ||
| Pathobiological Mechanisms | ZEB1 is a key transcription factor in EMT. It induces EMT by inhibiting the expression of E-cadherin, and enhances the invasive, metastatic and drug-resistant capabilities of tumor cells. | ||||
| Clinical Availability Status | Research verification: High expression of ZEB1 is associated with an increased risk of distant metastasis and poor prognosis in breast cancer. | ||||
| Notes and Dynamics | ZEB1 inhibitors can reverse the EMT phenotype and restore the sensitivity of tumor cells to chemotherapy. The related drugs are currently in the preclinical development stage. | ||||